NTRB
Nutriband Inc.
There isn't enough reported data to score NTRB yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
NTRB Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
NTRB's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NTRB PE Valuation
NTRB has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NTRB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect NTRB's losses to shrink, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NTRB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2025 | -$0.90 | -$0.13 |
| Q1 2025 | -$0.99 | -$0.30 |
| Q4 2024 | -$0.71 | -$0.07 |
| Q3 2024 | -$0.81 | -$0.25 |
| Q2 2022 | -$0.84 | -$0.43 |
| Q1 2022 | -$0.80 | -$0.36 |
| Q4 2021 | -$0.67 | -$0.42 |
| Q3 2021 | -$0.45 | -$0.09 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 170% for NTRB versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
NTRB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $437.5K | -30% |
| Q2 2026 | $433.4K | -35% |
| Q1 2026 | $400.7K | -38% |
| Q4 2025 | $346.1K | -46% |
| Q3 2025 | $622.5K | +41% |
| Q2 2025 | $667.4K | +63% |
| Q1 2025 | $642.4K | +22% |
| Q4 2024 | $645.8K | +51% |
NTRB's revenue has slid since its 2025 peak: $437,514 last quarter, down 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -204% | +118 points |
| Q2 2026 | -289% | -78 points |
| Q1 2026 | -255% | +611 points |
| Q4 2025 | -1121% | -900 points |
| Q3 2025 | -322% | -3.5 points |
| Q2 2025 | -212% | +251 points |
| Q1 2025 | -865% | -616 points |
| Q4 2024 | -221% | +182 points |
NTRB's operating margin was −204% last quarter, up 118 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NTRB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over NTRB on profitability, with a higher operating margin.
NTRB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$731.8K | +$507.4K |
| Q4 2025 | -$1.8M | -$695.9K |
| Q3 2025 | -$1.3M | +$269.3K |
| Q2 2025 | -$1.3M | -$502.2K |
| Q1 2025 | -$1.2M | -$471.9K |
| Q4 2024 | -$1.1M | +$7.7K |
| Q3 2024 | -$1.6M | -$587.5K |
| Q2 2024 | -$840.1K | -$87.6K |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with NTRB at down 71%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
NTRB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +9.3% | +1M shares |
| 3 years | +44% | +3.7M shares |
| 5 years | +84% | +5.6M shares |
| Available history | +92% | +5.8M shares |
NTRB has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NTRB Net Leverage
NTRB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
NTRB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.3 | Neutral |
| Stochastic | 48.5 | Neutral |
NTRB's weekly RSI is 55 (neutral) and its Stochastic is 48 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NTRB PE vs Healthcare Sector
NTRB has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NTRB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.47 | 7.7% below |
| 20 week MA | $5.16 | 16% above |
| 50 week MA | $4.51 | 32% above |
| 100 week MA | $5.54 | 7.8% above |
| 200 week MA | $4.69 | 27% above |
NTRB's trend is up, with a small recent dip: it's below only its 8-week average, and 27% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NTRB on trend strength, trading above more of its moving averages.
NTRB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $5.74 | $3.10 | -46% |
| 2022 | $3.10 | $3.59 | +16% |
| 2023 | $3.59 | $2.32 | -35% |
| 2024 | $2.32 | $3.85 | +66% |
| 2025 | $3.85 | $4.80 | +25% |
| 2026 YTD | $4.80 | $5.97 | +24% |
NTRB has finished higher in three of the last five years. It's up 24% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NTRB on returns for 2026, with the stronger performance.